Results 211 to 220 of about 313,407 (265)
Some of the next articles are maybe not open access.
Immunotherapies in acute leukemia
Therapies, 2022In the past decade, immunotherapy has emerged as one of the most promising field of therapeutic progress in acute leukemia. Antibody-drug conjugates are now combined to standard chemotherapy backbones in both acute myeloid (AML) and lymphoblastic leukemia (ALL).
Nicolas, Boissel, Florence, Rabian
openaire +2 more sources
Hematology, 2001
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum +3 more
openaire +2 more sources
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum +3 more
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2009
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire +2 more sources
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire +2 more sources
International Journal of Oncology, 1997
The acute leukemias continue to present a formidable challenge for which there is not yet a reliably curative 'standard approach' for the majority of adults with this family of diseases. In order to make progress in terms of curing these devastating diseases, we must understand leukemia biology on the clinical, cellular and molecular levels, with ...
openaire +2 more sources
The acute leukemias continue to present a formidable challenge for which there is not yet a reliably curative 'standard approach' for the majority of adults with this family of diseases. In order to make progress in terms of curing these devastating diseases, we must understand leukemia biology on the clinical, cellular and molecular levels, with ...
openaire +2 more sources
American Journal of Ophthalmology, 1979
A 71-year-old woman had a history of recent weight loss and bilateral decreased visual acuity, bilateral serous detachment, and mental depression. Fluorescein angiograms showed a myriad of retinal pigment epithelial leakage points. Despite extensive evaluation, the cause of her weight loss and ocular process remained uncertain until her death, when ...
M C, Kincaid, W R, Green, J S, Kelley
openaire +2 more sources
A 71-year-old woman had a history of recent weight loss and bilateral decreased visual acuity, bilateral serous detachment, and mental depression. Fluorescein angiograms showed a myriad of retinal pigment epithelial leakage points. Despite extensive evaluation, the cause of her weight loss and ocular process remained uncertain until her death, when ...
M C, Kincaid, W R, Green, J S, Kelley
openaire +2 more sources
Pediatric Clinics of North America, 1997
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +2 more sources
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +2 more sources
European Journal of Haematology, 2001
Abstract: Acute basophilic leukemia has recently been included into a revised classification of acute leukemias proposed by the WHO panel. Due to the rarity of the disease, consistent diagnostic criteria are lacking. We report on two cases of acute basophilic leukemia that occurred in our department during the last 10 yr.
A A, Giagounidis +5 more
openaire +2 more sources
Abstract: Acute basophilic leukemia has recently been included into a revised classification of acute leukemias proposed by the WHO panel. Due to the rarity of the disease, consistent diagnostic criteria are lacking. We report on two cases of acute basophilic leukemia that occurred in our department during the last 10 yr.
A A, Giagounidis +5 more
openaire +2 more sources
Pediatric Annals, 1978
Acute nonlymphoid leukemia (ANLL) is not an uncommon form of leukemia in children. The differential diagnosis is sometimes difficult, but there are a number of laboratory tests that can contribute useful information. Despite the introduction of several newer chemotherapeutic agents, only 50 to 60 percent of children with ANLL achieve complete ...
openaire +2 more sources
Acute nonlymphoid leukemia (ANLL) is not an uncommon form of leukemia in children. The differential diagnosis is sometimes difficult, but there are a number of laboratory tests that can contribute useful information. Despite the introduction of several newer chemotherapeutic agents, only 50 to 60 percent of children with ANLL achieve complete ...
openaire +2 more sources
The American Journal of Medicine, 1982
Abstract We examined the clinical features and therapeutic response of a group of patients with acute leukemia and hypocellular bone marrow. Therapists have generally avoided, delayed or modified therapy because of hypocellularity. We demonstrated not only that aggressive therapy is possible, but also that the remission rate is high (complete ...
R B, Howe, C D, Bloomfield, R W, McKenna
openaire +2 more sources
Abstract We examined the clinical features and therapeutic response of a group of patients with acute leukemia and hypocellular bone marrow. Therapists have generally avoided, delayed or modified therapy because of hypocellularity. We demonstrated not only that aggressive therapy is possible, but also that the remission rate is high (complete ...
R B, Howe, C D, Bloomfield, R W, McKenna
openaire +2 more sources
Acute megakaryoblastic leukemia
Blood, 2013![Figure][1] A 46-year-old woman presented with diffuse bone pain. She had a history of acute myeloid leukemia with minimal differentiation (AML-M0) and normal karyotype diagnosed 15 months ago, achieved complete remission (CR) 1 month after beginning induction chemotherapy, and received ...
Armin, Rashidi, Stephen I, Fisher
openaire +2 more sources